Advertisement

Cannabinoids Pharmacology, Abuse, and Addiction

Living reference work entry

Abstract

Cannabis has a long history of therapeutic use and misuse. Δ-9-tetrahydrocannabinol (THC) was identified as the principle psychoactive component of cannabis in 1965. For the next two decades, cannabis research focused on THC pharmacology. Smoked or inhaled THC rapidly delivers the drug to the brain increasing its abuse liability. Once present in the brain THC hijacks important functions of the endogenous cannabinoid system modulating the release and reuptake of a wide variety of other neurotransmitters. THC disrupts memory, executive function, attention, hormone secretion, motor initiation and movement, decision-making, mood, and others. An individual using less than daily cannabis is considered an occasional user, while one who generally consumes the drug daily is considered a frequent cannabis user. The brain adapts to continuous CB1-cannabinoid receptor stimulation by reducing the density of receptors, but this can be reversed over weeks of sustained cannabis abstinence.

One of the major public health and safety considerations at this time of increasing cannabis medicalization and legalization is the effects on brain development in cannabis smokers that initiate use prior to the age of 17 years. The connections between different areas of the brain may not develop normally in these frequent adolescent cannabis smokers, and the changes in brain development may not be reversible. Another major public concern is the increased incidence of cannabis-impaired driving. Since the 1970s the incidence of drunk driving decreased, although it remains the major killer on the roads; however, drugged driving and, in particular, cannabis-impaired driving increased. The prevalence of THC in drivers’ blood or oral fluid increased 48 % between the 2007 and 2013–2014 National Roadside Surveys.

Importantly, individuals predisposed to develop schizophrenia or psychosis may have their condition exacerbated by cannabis intake and frequently may have their first schizophrenic break occur earlier following cannabis smoking. But the therapeutic potential of cannabinoids such as cannabidiol (CBD) or mixed THC and CBD plant extracts are currently being investigated to treat a wide variety of diseases. CBD has neuroprotective properties that are exploited as treatments for Davet’s syndrome, treatment resistant seizures in children refractory to other available therapies. The discovery of the cannabinoid receptors, CB1 and CB2, and identification of anandamide and other endogenous cannabinoids, improved our understanding of THC effects on the brain and mechanisms of cannabis addiction. Cannabis is addictive and is the principal drug of abuse for 75 % of 12–17 year olds seeking drug treatment. It is an exciting and concerning time for cannabis research. Potential new therapies for a wide variety of disorders co-occur with increased cannabis dependence and treatment demands, and concern over the long-term effects of frequent cannabis abuse in adolescents and the increased morbidity and mortality of cannabis-impaired driving.

Keywords

Abuse Addiction Brain development Brain imaging Brain damage Cannabidiol Cannabinoids Cannabinoid receptor Cannabinoid therapy Cannabis Cannabis dependence Cannabis-impaired driving CB1 CB2 Chronic frequent smoker DAWN Driving under the influence of drugs Endogenous cannabinoid system fMRI Marijuana Neuroadaptation Novel psychoactive substances Oral Occasional smoker Pharmacodynamics Pharmacokinetics Pharmacology Pharmacotherapies Rimonabant Sativex Smoking Synthetic cannabinoids Δ-9-Tetrahydrocannabinol THC TEDS 

References

  1. Andreasson S, Allebeck P, Engstrom A et al (1987) Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2:1483–1486CrossRefPubMedGoogle Scholar
  2. Anthony JC, Warner LA, Kessler RC (1994) Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 2:244–268CrossRefGoogle Scholar
  3. Bergamaschi MM, Karschner EL, Goodwin RS et al (2013) Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers’ blood on per se drugged driving laws. Clin Chem 59:519–526CrossRefPubMedPubMedCentralGoogle Scholar
  4. Berning A, Compton R, Wochinger K (2015) Results of the 2013–2014 national roadside survey of alcohol and drug use by drivers. National Highway Traffic Safety Administration, DOT HS 812 118, Washington, DCGoogle Scholar
  5. Bosker WM, Karschner EL, Lee D et al (2013) Psychomotor function in chronic cannabis smokers during sustained abstinence. PLoS One 8(1):e53127CrossRefPubMedPubMedCentralGoogle Scholar
  6. Compton R, Berning A (2009) Results of the 2007 national roadside survey of alcohol and drug use by drivers. National Highway Traffic Safety Administration, Washington, DCCrossRefGoogle Scholar
  7. Couper FJ, Peterson BL (2014) The prevalence of marijuana in suspected impaired driving cases in Washington State. J Anal Toxicol 38:569–574CrossRefPubMedGoogle Scholar
  8. Desrosiers NA, Himes SK, Scheidweiler KB et al (2014) Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem 60:631–643CrossRefPubMedGoogle Scholar
  9. Desrosiers NA, Ramaekers JG, Chauchard E et al (2015) Smoked cannabis’ psychomotor and neurocognitive effects in occasional and frequent smokers. J Anal Toxicol 39:251–261CrossRefPubMedPubMedCentralGoogle Scholar
  10. Devane WA, Dysarz FA 3rd, Johnson MR et al (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605–613PubMedGoogle Scholar
  11. Devane WA, Hanus L, Breuer A et al (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946–1949CrossRefPubMedGoogle Scholar
  12. Di Forti M, Marconi A, Carra E et al (2015) Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case–control study. Lancet Psychiatr 2:233–238CrossRefGoogle Scholar
  13. Drummer OH, Gerostamoulos J, Batziris H et al (2004) The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. Accid Anal Prev 36:239–248CrossRefPubMedGoogle Scholar
  14. Goodwin RS, Gustafson RA, Barnes A et al (2006) Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids. Ther Drug Monit 28:545–551CrossRefPubMedGoogle Scholar
  15. Gorelick DA, Goodwin RS, Schwilke E et al (2012) Tolerance to effects of high-dose oral Δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers. J Anal Toxicol 37:11–16CrossRefPubMedPubMedCentralGoogle Scholar
  16. Hartman RL, Brown TL, Milavetz G et al (2015a) Cannabis effects on driving lateral control with and without alcohol. Drug Alcohol Depend 154:25–37CrossRefPubMedGoogle Scholar
  17. Hartman RL, Brown TL, Milavetz G et al (2015b) Controlled cannabis vaporizer administration: blood and plasma cannabinoids with and without alcohol. Clin Chem 61:850–869CrossRefPubMedGoogle Scholar
  18. Hirvonen J, Goodwin RS, Li CT et al (2012) Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry 17:642–649CrossRefPubMedGoogle Scholar
  19. Huestis MA (2010) Marijuana. In: Levine B (ed) Principles of forensic toxicology, 3rd edn. AACC Press, Washington, DCGoogle Scholar
  20. Huestis MA, Cone EJ (1998) Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J Anal Toxicol 22(6):445–454CrossRefPubMedGoogle Scholar
  21. Huestis MA, Smith ML (2005) Pharmacokinetics and metabolism of the plant cannabinoids. In: Pertwee R (ed) Handbook of experimental pharmacology (Cannabinoids), vol 168. Springer, New York, p 660, Fig. 1Google Scholar
  22. Huestis MA, Henningfield JE, Cone EJ (1992) Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 16:276–282CrossRefPubMedGoogle Scholar
  23. Huestis MA, Gorelick DA, Heishman SJ et al (2001) Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 58:322–330CrossRefPubMedGoogle Scholar
  24. Johnston LD, O’Malley PM, Miech RA et al (2014) Monitoring the Future national results on drug use: 1975–2013; overview, key findings on adolescent drug use. Institute for Social Research, The University of Michigan, Ann ArborGoogle Scholar
  25. Karschner EL, Darwin WD, McMahon RP et al (2011) Subjective and physiological effects after controlled Sativex and oral THC administration. Clin Pharmacol Ther 89:400–407CrossRefPubMedGoogle Scholar
  26. Lee D, Schroeder JR, Karschner EL et al (2014) Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence within a closed residential environment. Am J Addict 23:234–242CrossRefPubMedPubMedCentralGoogle Scholar
  27. Lopez-Quintero C, Hasin DS, de Los Cobos JP et al (2011) Probability and predictors of remission from life-time nicotine, alcohol, cannabis or cocaine dependence: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Addiction 106:657–669CrossRefPubMedGoogle Scholar
  28. Lowe RH, Abraham TT, Darwin WD et al (2009) Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend 105:24–32CrossRefPubMedPubMedCentralGoogle Scholar
  29. Mechoulam R, Gaoni Y (1965) A total synthesis of dl-delta-1-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 87:3273–3275CrossRefPubMedGoogle Scholar
  30. Pope H, Gruber A, Hudson J et al (2001) Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 58:909–915CrossRefPubMedGoogle Scholar
  31. Pope HG Jr, Gruber AJ, Hudson JI et al (2003) Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend 69:303–310CrossRefPubMedGoogle Scholar
  32. Ramaekers JG, Kauert G, Theunissen EL et al (2009) Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol 23:266–277CrossRefPubMedGoogle Scholar
  33. Relman A (ed) (1982) Marijuana and health (Report of a study by a committee of the Institute of medicine, Division of health sciences policy). National Academy Press, Washington, DCGoogle Scholar
  34. Schwilke EW, Schwope DM, Karschner EL et al (2009) Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem 55:2180–2189CrossRefPubMedPubMedCentralGoogle Scholar
  35. Schwope DM, Karschner EL, Gorelick DA et al (2011a) Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem 570:1406–1414CrossRefGoogle Scholar
  36. Schwope DM, Karschner EL, Gorelick DA, Huestis MA (2011b) Identification of recent cannabis use: whole blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem 57(10):1406–1414CrossRefPubMedPubMedCentralGoogle Scholar
  37. Smith AM, Fried PA, Hogan MJ et al (2006) Effects of prenatal marijuana on visuospatial working memory: an fMRI study in young adults. Neurotoxicol Teratol 28:286–295CrossRefPubMedGoogle Scholar
  38. Smith AM, Longo CA, Fried PA, Hogan MJ, Cameron I (2010) Effects of marijuana on visuospatial working memory: an fMRI study in young adults. Psychopharmacology (Berl) 210:429–438CrossRefGoogle Scholar
  39. Treatment Episode Data Set (TEDS): 2002–2012 (2014) National admissions to substance abuse treatment services. BHSIS series S-71, HHS publication no. (SMA) 14–4850. Substance Abuse and Mental Health Services Administration, Rockville, p 75Google Scholar
  40. Volkow ND, Baler RD, Compton WM et al (2014) Adverse health effects of marijuana use. N Engl J Med 370:2219–2227CrossRefPubMedPubMedCentralGoogle Scholar

Authors and Affiliations

  1. 1.Chemistry and Drug Metabolism, IRP, National Institute on Drug Abuse National Institutes of HealthBaltimoreUSA
  2. 2.University of Maryland School of MedicineBaltimoreUSA
  3. 3.US Army Forensic Toxicology Drug Testing LaboratoryFort George G MeadeUSA

Personalised recommendations